

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 September 2005 (09.09.2005)

PCT

(10) International Publication Number
WO 2005/082909 A1

(51) International Patent Classification⁷: **C07D 491/04**,
A61K 31/436, A61P 29/00

(21) International Application Number:
PCT/US2005/006627

(22) International Filing Date: 24 February 2005 (24.02.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/548,154 25 February 2004 (25.02.2004) US

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/548,154 (CIP)
Filed on 25 February 2004 (25.02.2004)

(71) Applicant (for all designated States except US): **LIGAND
PHARMACEUTICALS INCORPORATED** [US/US];
10275 Science Center Drive, San Diego, CA 92130 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ZHI, Lin** [US/US];
3988 Via Cangrejo, San Diego, CA 92130 (US). **ARDECKY, Robert, J.** [US/US]; 3461 Calle Mar-
garita, Encinitas, CA 92024 (US). **PHILLIPS, Dean**
[US/US]; 749 Camino Magnifico, San Marcos, CA 92069
(US). **TYHONAS, John, S** [US/US]; 926 Via Cedro,
Chula Vista, CA 91910 (US). **KARANEWSKY, Donald,**
S. [US/US]; 1797 Continental Lane, Escondido, CA 92029
(US). **HIGUCHI, Robert, I.** [US/US]; 434 Marview
Drive, Solana Beach, CA 92075 (US). **HUDSON, An-**
drew, Richard [GB/US]; 3110 Laurel Street, San Diego,
CA 92104 (US). **ROACH, Steven, L.** [US/US]; 5210
Fiore Terrace #L305, San Diego, CA 92122 (US). **VAS-**
SAR, Angie, C. [US/US]; 13238 Wimberly Square #195,
San Diego, CA 92128 (US). **LI, Yongkai** [CN/US]; 935
Babauta Road #7, San Diego, CA 92129 (US). **ADAMS,**
Mark, E. [US/US]; 3512 Seahorn Circle, San Diego,
CA 92130 (US). **VALDEZ, Lino, Juan** [US/US]; 3350
McGraw Street, San Diego, CA 92122 (US). **CUERVO,**
Catalina [US/US]; 9115 Judicial Drive #4115, San Diego,
CA 92122 (US).

(74) Agents: **SEIDMAN, Stephanie, L.** et al.; Fish & Richard-
son P.C., 12390 El Camino Real, San Diego, CA 92130
(US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN,
YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,
BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA,
ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ,
NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,
BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG)

Published:

— with international search report

[Continued on next page]

(54) Title: GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY



(57) Abstract: Provided herein are compounds of Formula (I) and pharmaceuti-
cally acceptable derivatives thereof. Certain of such compounds are selective glu-
cocorticoid receptor modulators and/or selective glucocorticoid binding agents.
Also provided are methods of making and using such compounds, including, but
not limited to, using such compounds for treating various conditions.



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.